Kornimate/medical-research-clean huggingface dataset:
the use of glyceryl trinitrate patches in arteriovenous fistulas

Conditions: Renal Failure

Summary: the aim of the study is to determine whether the application of a glyceryl trinitrate patch (gtn patch) helps arteriovenous fistulas, created for renal dialysis access, mature so that they can be used.

patients with end stage renal failure on haemodialysis must have a mechanism for achieving access to their vascular system for dialysis. arteriovenous fistulas (surgically created connections between the artery and vein) are critical for the majority of patients. not all the fistulas that are created work, a proportion fail early on and need to be revised or an alternative fistula created. a recent multicentre study demonstrated a 40% primary failure rate(1). in an attempt to increase the numbers of fistulae that reach maturation sufficient for dialysis access cannulation some renal centres apply gtn patches to the fistula at the time of surgery. it is thought that this works by increasing the size of the blood vessels and promoting blood flow through them and some preliminary work seems to support this(2). the evidence for the use of gtn patches in arteriovenous fistula creation is theoretical or based on preliminary work rather than robust evidence. similarly no evidence exists within the literature to determine the safety and definite efficacy of this procedure in this population. we propose to conduct a double-blinded randomised control trial to answer the study question: does the application of a gtn patch increase the venous outflow diameter post fistula formation and does this result in improved fistula patency.

Eligibility criteria:
inclusion criteria: * primary arteriovenous fistulas * brachiocephalic * radiocephalic (both proximal and distal) * \>18 yrs old * diabetics and smokers will be eligible for inclusion exclusion criteria: * all complex vascular access procedures * re-do brachiocephalic and radiocephalic fistulas * brachiobasilic fistulas * prosthetic grafts * cardiovascular dysfunction * hypotension (systolic \<90) * obstructive cardiomyopathy * severe aortic stenosis (gradient \>40mmhg) * confirmed myocardial infarction within the last 6 months * marked anaemia (hb\<8) * migraine * medications * sildenafil * pre-existing nitrate use * nitrate allergy * closed-angle glaucoma * chronically raised intra-cranial pressure * history of hypothyroid disease * \< 18 years old

Keywords: arteriovenous fistula patency gtn patch
elbow pain in hemodialysis patients and its effect on daily living activities of the patients

Conditions: End Stage Renal Disease

Summary: the study will include the patients undergoing hemodialysis.

the study will include the patients undergoing hemodialysis. the patients with surgery at upper extremity in last 3 months, the presence of conditions such as cancer, chronic hearing loss and neurologic diseases affect the interview will be excluded. sociodemographic properties which include age, gender, duration of dialysis, educational level, comorbid diseases, vascular access area, hand dominancy will be asked. the beck depression inventory (bdi), the nottingham health profile (nhp), the disabilities of the arm, shoulder and hand score (q-dash) and visual analogue scale (vas) will applied to all patients. all the demographic results and vascular access area for hemodialysis will be detected. all data for normality will be tested by using kolmogorov-smirnov test. to compare the differences between groups, mann whitney u test will be used

Eligibility criteria:
inclusion criteria: * being over 18 years old having hemodialysis treatment exclusion criteria: * any surgical operation at upper extremity in last 3 months, the presence of conditions such as cancer, chronic hearing loss and neurologic diseases can affect the interview.

Keywords: musculoskeletal pain elbow pain hemodialysis
bizarreness and anomalous self experiences in schizophrenia

Conditions: Schizophrenia

Summary: several authors suggest that the specific experience felt in clinical encounter, called praecox feeling, is directly linked to the psychopathology of schizophrenia. however, determining factors of this phenomena, whether cognitive or subjective, remains poorly studied. furthermore, self-disorders are alterations of the first-person experience regarded as specific of the disease. the investigators plan to study in an exploratory way the phenomenological and subjective links between praecox feeling and self disorders determinants, while hypothesizing that the clinician's praecox feeling can be positively correlated to sds, as our main objective.

several authors suggest that the specific experience felt in clinical encounter, called praecox feeling, is directly linked to the psychopathology of schizophrenia. however, subjective, cognitive or neurophysiologic aspects of this phenomena remains poorly studied. furthermore, self-disorders (sd) are alterations of the first-person experience and of sense of agency, regarded as specific of schizophrenia. unlike praecox feeling, clinical, cognitive and neuropsychological determinants of sd are increasingly studied. the investigators plan to study in an exploratory way the links between praecox feeling and sds determinants, while hypothesizing that the clinician's praecox feeling can be positively correlated to sds, as our main objective. as a secondary outcome, the investigators will control this correlation by a comparison between sds evaluation and clinician subjectivity. the present study also plan to evaluate the associations between praecox feeling and clinical features, low and high cognitive level with attentional and social cognition evaluations. the first step of the research project is to implement this exploratory design in a transversal multicentric setting between centers with a limited number of participants and without follow-up.

Eligibility criteria:
inclusion criteria: * people with a diagnosis of schizophrenia according to the diagnostic and statistical manual of mental disorders (dsm-v) criteria. * psychiatric medical situation judged clinically stable : no change of main antipsychotic in treatment in last 15 days. * people who has given his non-opposition * patients affiliated to a social security system exclusion criteria: * previous meeting of the participant with one of the investigators involved in the clinical assessment and scoring of the study scales. * person with a moderate to severe intellectual disability (clinical criteria). * person with a neurological pathology with cognitive impact * patients with legal protection

Keywords: praecox feeling self-disorders subjectivity cognition
study to compare the safety and pharmacokinetics of pk101 with coadministration of the two separate drugs

Conditions: Arthritis

Summary: the purpose of this study is to compare the safety and pharmacokinetics of pk101(fixed-dose combination of pk101-001 and pk101-002) with coadministration of the two separate drugs in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy adults ≥ 19 years of age (on the day of screening) * body weigth ≥50.0kg, 18.5kg/(m)\^2 ≤ (bmi) ≤30.0kg/(m)\^2 * no congenital or chronic diseases and no abnormal signs determined by medical examinations * not abnormal or not clinical significant lab values * understand the requirements of the study and voluntarily consent to participate in the study. exclusion criteria: * clinically significant disease with liver, renal, neurologic, respiratory, digestive, endocrine, hemato-oncology, urologic, cardiovascular, musculoskeletal, psychiatric system * subjects who have hypersensitivity for investigational products * ast or alt \> 2\*uln, r-gtp \> 1.5\*uln, blood creatinine \> uln (uln, upper limit of normal) * sbp ≥ 140 mmhg or\< 90 mmhg, dbp ≥ 90 mmhg or \< 60 mmhg * subjects who were administered below medications within 30 days (barbiturates, drugs of induced or suppressive drug metabolizing enzyme, etc) * subjects who previously participated in other clinical trials or bioequivalence test within 6 months * subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing.
diagnosis and prediction of pre-eclampsia by using congo red dot test in bangladesh and mexico

Conditions: Preeclampsia

Summary: a cross sectional study design will evaluate the diagnostic value of the crd test to the pregnant women attending the dhaka medical college hospital and hospital materno-infantil inguarán, tertiary level facilities in bangladesh and mexico city.

a cross sectional study design will evaluate the diagnostic value of the congo red dot test to the pregnant women attending the dhaka medical college hospital and hospital materno-infantil inguarán, tertiary level facilities in bangladesh and mexico city. women attending the hospital with clinically confirmed cases of preeclampsia and clinically healthy women who deliver at term will be eligible for the study. investigators will enroll about 200 women at each facility. investigators will target the following women for enrollment: women with clinical diagnosis of preeclampsia (severe, mild or superimposed) (n=100); and clinically healthy women who deliver at term (n=100). the purpose of the research is to determine the clinical utility of congophilia (affinity for the dye congo red) in the diagnosis and prediction of preeclampsia. investigators will determine the diagnostic value of this test by testing the urine sample provided to determine the presence or absence of proteinuria or congophilia.

Eligibility criteria:
inclusion criteria: * pregnant * willing to provide a urine sample * eligible to consent to research according to local laws and regulations * present with a clinical diagnosis of preeclampsia (severe, mild or superimposed) or clinically healthy and delivering at term exclusion criteria: -none

Keywords: congo red dot test
a study using botulinum toxin type a as headache prophylaxis for migraine patients with frequent headaches

Conditions: Migraine Disorders

Summary: this is a 60 week study including a double-blind phase followed by an open-label extension phase.


Eligibility criteria:
inclusion criteria: * frequent migraine (\>=15 headache days per month) * \>=4 distinct headache episodes lasting \>=4 hours * \>=50% of baseline headache days migraine/probable migraine days exclusion criteria: * previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype * any medical condition that puts the patient at increased risk with exposure to botox * diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache * use of prophylactic headache medication within 28 days prior to week -4 * unremitting headache lasting continuously throughout the 4-week baseline period * known or suspected temporomandibular disorders (tmd) * diagnosis of fibromyalgia * beck depression inventory score \>24 at week-4 * psychiatric problems that may have interfered with study participation
pet imaging study using [11c]pib in subjects with ad & healthy volunteers

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to investigate the radiotracer \[11c\] pib in participants with probably alzheimer's disease (ad) and healthy age-matched controls.

the objectives of the study are: 1. to perform pet scans with \[11c\]pib to use for direct (i.e., same-subjects) comparison of \[11c\]pib and \[18f\]av-45 2. to establish the most effective and reliable pet imaging method to detect amyloid deposition in ad, in order to understand disease progression and subsequently evaluate treatment effects. 3. to ascertain a pet imaging method that will minimize discomfort for subjects, thus increasing the potential for clinical follow-up scans, by reducing the patient burden and potential cost of future pet examinations. a separate protocol/study will be conducted using \[18f\] av-45. participants who enroll in this protocol using \[11c\] pib will be consented to participate in the \[18f\] av-45 (irb # na_00033155) protocol/study as it is a mandatory requirement that participants participate in both protocols.up to 20 participants with mild to moderate alzheimer's disease and 10 healthy volunteers will participate in this study.

Eligibility criteria:
inclusion criteria: * male or female subjects at least 18 years of age * subjects who in the opinion of the investigator based on medical history and physical exam can tolerate the pet scan procedures exclusion criteria: * have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances * have current clinically significant cardiovascular disease. * have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse * have a clinically significant infectious disease, including acquired immune deficiency syndrome (aids) or human immunodeficiency virus (hiv) infection or previous positive test for hepatitis * women of childbearing potential must not be pregnant (negative urine beta-hcg at the time of screening and negative urine beta-hcg on the day of imaging) or lactating at screening or at day of imaging * have a history of relevant severe drug allergy or hypersensitivity (relevant severe drug allergies should be determined by the pi, and any questions about a subject's eligibility can be directed to avid. if a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study with a novel compound * have received an investigational medication within the last 30 days. current clinically significant or unstable medical comorbidities, as indicated by history or physical exam * have received a radiopharmaceutical for imaging or therapy within the past 7 days prior to the imaging session for this study * body weight \> 300 pounds * history of significant radiation exposure * participants with pacemakers, implanted electronic hearing devices, aneurysm clips, shrapnel, unallowed prosthetic or other metallic device in their bodies * pre-existing cns disease (other than dementia), endocrine, or severe cardiovascular disease (mi, cabg, angioplasty)
recycling of chronic smokers to sustained abstinence

Conditions: Cardiovascular Diseases; Heart Diseases; Lung Diseases

Summary: to develop and to test a brief telephone intervention following clinic treatment for smoking cessation.

design narrative: a total of 1,083 chronic smokers were randomly assigned either to a traditional state-of-the-art smoking cessation clinic or to the clinic supplemented by telephone support for recycling. telephone outreach consisted of three separate rounds of intervention three months, nine months, and 21 months after the targeted date for quitting in the smoking cessation clinics. telephone calls to abstinent subjects reinforced success and offered advice and support in coping with difficult situations. calls to relapsers and nonabstainers debriefed concerning the relapse episode (as appropriate) and encouraged subjects to initiate concrete action toward quitting including setting a quit date. subjects were offered self-help materials as well as referrals to more intensive programs. follow-up data collection was separate from recycling contacts and occured six, 12, 24, and 34 months after the initial smoking cessation clinics. projected longterm sustained abstinence rates were 35 percent for recycling and 25 percent for the clinic only comparison. if results were as predicted, an effective low-cost telephone outreach protocol was made available that could dramatically assist in smoking cessation and thereby substantially reduce cardiovascular disease.

Eligibility criteria:
no eligibility criteria
use of axillary ultrasound to guide breast cancer management in the genomic assay era

Conditions: Axillary Ultrasound

Summary: the investigators aimed to determine if axillary ultrasound can reliably distinguish between patients with limited or high nodal burden, so that the patients with limited nodal burden can potentially avoid chemotherapy and instead receive upfront surgery followed by gene assay testing.


Eligibility criteria:
inclusion criteria: * breast cancer patients with t1-3, hr-positive and her2-negative disease. * aged≥ 50 years old * had axillary ultrasound prior to operation * axillary lymph node dissection exclusion criteria: * patients with neoadjuvant chemotherapy * bilateral cancers
opt-302 with ranibizumab in neovascular age-related macular degeneration (namd)

Conditions: Neovascular Age-related Macular Degeneration

Summary: a 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. primary efficacy will be determined at week 52.


Eligibility criteria:
inclusion criteria: * active subfoveal cnv lesion or juxtafoveal cnv lesion with foveal involvement that is secondary to amd in the study eye. * an etdrs bcva score between 60 and 25 (inclusive) letters in the study eye. main exclusion criteria: * any previous treatment for neovascular amd. * clinically significant ocular disorders (other than neovascular amd), which may interfere with assessment of bcva, assessment of safety, or fundus imaging. * any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study. * additional inclusion/exclusion criteria may apply
comparison between erector spinae plane block and transversus abdominis plane block on postoperative analgesia after total abdominal hysterectomy

Conditions: Uterine Diseases

Summary: this study aims to compare the ultrasound-guided bilateral erector spinae block versus the ultrasound-guided bilateral transversus abdominis plane block on postoperative analgesia after total abdominal hysterectomy.


Eligibility criteria:
inclusion criteria: 1. patients american society of anesthesiologists physical status (asa) i and ii. 2. female sex. 3. age between 40 to 60 years old. 4. scheduled for elective total abdominal hysterectomy surgeries. exclusion criteria: 1. patient's refusal. 2. patients who received long-acting opioids preoperatively. 3. patients with bleeding disorders and coagulopathy. 4. infection at the injection site. 5. allergy to local anesthetics. 6. patients with significant cognitive dysfunction. 7. patients with diabetic neuropathy. 8. patients with uncontrolled hypertension or diabetes. 9. patients with advanced cardiac, respiratory, hepatic or renal disease. 10. patients with viral hepatitis or hiv. 11. surgeries which have been complicated or prolonged (more than 150 mins).

Keywords: espb, tap
effectiveness verification of using hydrogen inhalation to improve fatigue, pain and quality of life in cancer patients

Conditions: Head and Neck Cancer; Quality of Life; Pain; Sleep; Inhalation; Gas

Summary: there are two recruitment methods for this study, which are mainly based on the co-principal investigator dr. chih-jen huang recommendation of eligible subjects and poster recruitment methods. when the subjects return to the outpatient clinic, those who meet the conditions for admission will be recommended by dr. chih-jen huang. if they agree to participate in the trial, they will sign the informed consent form, and instruct the subjects to use their mobile phones to scan the qr code of the relevant introduction of the trial first, and complete the test. the first questionnaire measurement before hydrogen inhalation; if the subjects are recruited by the poster, they can contact the host of tongtong through the qr code on the poster or the contact number, and sign the consent form for the first time during the return visit. questionnaire measurement.

this study is a randomized controlled trial, and an experimental group and a waiting list group will be used to verify the interventional effect of hydrogen. for patients diagnosed with head and neck cancer who received radiation therapy or combined chemotherapy (ccrt) and met the inclusion criteria, the study was included after the study description and the consent of the trial were obtained. investigators will be included, and the subjects will be numbered by the research executor (co-principal investigator), and the number will be handed over to the project host, who will assign the subjects to the experimental group or the control group according to the random case allocation table generated in advance. the manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. the research executor will pay attention to the line group on the first day of installation, and obtain the pre-test basic value data through the google form after (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started. the control group was inhaled with the same machine, but the gas was only ordinary air, which was used as a placebo control; after the experiment was over, if the moderator of the air inhalation group explained the plan, hydrogen inhalation would be given in the follow-up month for 1 month.

Eligibility criteria:
inclusion criteria: * adults over the age of 20 * pathological diagnosed with head and neck cancer * received radiation therapy or combined chemotherapy * can use mandarin or taiwanese to communicate and have normal cognition exclusion criteria: * with chronic obstructive pulmonary disease * having contraindications to use of low flow oxygen * feeling uncomfortable using nasal cannula for inhalation

Keywords: head and neck cancer hydrogen cancer related symptom
outcomes in hospitalized older patients with covid-19

Conditions: Coronavirus Infection; Sars-CoV2; Elderly Infection; Old Age; Debility

Summary: in december 2019, the first patients infected with the 2019 novel coronavirus (2019-ncov) were diagnosed in wuhan. the clinical presentation and course of severe acute respiratory syndrome-cov-2 (sars-cov-2) infection is poorly understood in older patients and is certainly different from the general population. this project is designed to better understand and to determine clinical, biological and radiological markers of poor adverse outcomes in hospitalized older patients diagnosed with covid-19.


Eligibility criteria:
inclusion criteria: * diagnosis of covid-19, defined by a positive polymerase chain reaction (pcr) test for sars-cov-2 detection, obtained by a nasopharyngeal swab or sputum sample. * or patients with negative virus detection in the pcr test, but with a high clinical suspicion will also be considered with covid-19. exclusion criteria: - presence of document indicating a refusal to participate in a research study.
rapid detection of pseudomonas aeruginosa in bronchoalveolar lavage fluid using label-free single-particle imaging technology and assessment of post-treatment efficacy in patients with pseudomonas aeruginosa infection

Conditions: Rapid Detection; Pseudomonas Aeruginosa Infection

Summary: the aim of this study is to observe specimens of bronchoalveolar lavage fluid from patients using a reflection enhanced dark-field scattering microscopy. by observing parameters such as the size, morphology, scattering intensity, and movement speed of pathogens, combined with the clinical characteristics of patients, a rapid diagnosis of pseudomonas aeruginosa infection can be made. at the same time, the bronchoalveolar lavage fluid samples of patients infected with pseudomonas aeruginosa before and after treatment were compared, and the quantity and vitality of pseudomonas aeruginosa were observed to judge the efficacy of antibiotics.


Eligibility criteria:
inclusion criteria: * aged 18 years and above * after admission, pseudomonas aeruginosa was cultured in bronchoalveolar lavage fluid or lower respiratory tract aspirates exclusion criteria: * age under 18 years old or over 90 years old * pregnancy, lactation period -